期刊文献+

探讨^(18)F-FDG SPECT/CT在胃癌疗效评价中的价值 被引量:1

Study of Value of ^(18)F-FDG SPECT/CT in Evaluation of Treatment Response in Gastric Cancer
在线阅读 下载PDF
导出
摘要 目的探讨18F-FDG SPECT/CT(18F-FDG coincidence single photon emission computed tomography/multi-detector computed tomography,18F-FDG SPECT/CT)所测定T/B值在胃癌临床疗效评价的价值。方法对31例未治疗的新发的原发性胃癌患者化疗前后进行MDCT增强扫描与18F-FDG SPECT/CT断层显像并测定T/B值。根据患者MDCT的疗效判定结果 ,初步探讨18F-FDG SPECT/CT的T/B值进行疗效评价的标准。结果 18F-FDG SPECT/CT中的T/B值下降率R△T/B与肿瘤最大径之和的下降率R△MD存在显著的直线相关(相关系数Rs=0.867,P<0.001);18F-FDG SPECT/CT中的R△T/B预测胃癌疗效的ROC曲线图的面积为0.943,其准确率为94.3%。若分别设R△T/B为35%、40%为基线,判定客观缓解OR(Objective remission,OR,CR+PR)的灵敏度分别为100%、85.7%,特异度94.1%、100%,阳性预测值93.3%、100%,阴性预测值100%、89.5%;判定有效率RR的结果分别为48.4%、38.7%。结论胃癌T/B值的改变率进行疗效评价具有较高的准确性,我们推荐T/B值下降35%以上作为临床判定客观缓解、无缓解的分界点。 Objective To Study the value of in 18F-FDG SPECT/CT (18F-FDG coincidence single photon-emission computed tomography/multi-detector computed tomography) in the evaluation of treatment response in gastric cancer. Methods MDCT (multi-detector computed tomography) enhancement scanning and 18F-FDG SPECT/CT was performed in 31 untreated patients with diagnosed gastric cancer. Then, chemotherapy with FOLFOX4 4Cycles was administrated on the 31 patients. 2 weeks after four Cycles of chemotherapy, both MDCT and 18F-FDG SPECT were performed in 31 patients.Criterion in MDCT was used to evaluate the treatment response. Then, the value of T/B was discussed by the treatment response.Results Kappa coefficient of the values of R△T/B [1-(T/B)after chemotherapy/(T/B)before chemotherapy] of 18 F-FDG SPECT/CT and R△MD (1-MaxiDiameterafter chemotherapy/MaxiDiameterbefore chemotherapy) of MDCT is 0.867(P0.01).The accuracy of R△T/B to predict the treatment response is 94.3%. If we make the base line of R△T/B as 35%, The sensitivity, specificity, positive predictive value,negative predictive value of 18F-FDG SPECT/CT were 100%, 94.1%,93.3% and 100% respectively. If R△T/B is 40%,the results are 85.7%,100%,100% and 89.5% respectively. Conclusion The changed rate of the value of T/B in 18F-FDG SPECT/CT in gastric cancer is accurate and feasible. We recommend the value of T/B decrease more than 35% as the demarcation of Objective remission and No remission.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2010年第6期679-682,共4页 Cancer Research on Prevention and Treatment
关键词 胃肿瘤 X线计算机体层成像 放射性核素显像 氟放射性同位素 疗效 Gastric Neoplasms X-ray computed tomography Radionuclide imaging Fluorine radioisotopes Treatment Response
作者简介 赖灿辉(1982-),男,硕士,住院医师,主要从事中西医结合肿瘤内科治疗
  • 相关文献

参考文献2

二级参考文献30

  • 1Kato H,Kuwano H,Nakajima M,et al.Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer[J].Am J Surg,2002,184(3):279-283.
  • 2Stail A,Ott K,Schwaiger M,et al.Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET[J].Eur J Nucl Med Mol Imaging,2004,31(11):1471-1478.
  • 3Amthauer H,Denecke T,Rau B,et al.Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer:correlation with endorectal ultrasound and histopathology[J].Eur J Nucl Med Mol Imaging,2004,31(6):811-819.
  • 4Pottgen C,Levegrun S,Theegarten D,et al.Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy[J].Clin Cancer Res,2006,12(1):97-106.
  • 5Avril N,Sassen S,Schmalfeldt B,et al.Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced stage ovarian cancer[J].J Clin Oncol,2005,23 (30):7445 -7453.
  • 6Dose Schwarz J,Bader M,Jenicke L,et al.Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET[J].J Nucl Med,2005,46(7):1144-1150.
  • 7Kim S J,Kim S K,Lee E S,et al.Predictive value of[18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy[J].Ann Oncol,2004,15 (9):1352-1357.
  • 8Schelling M,Avril N,Nahrig J,et al.Positron emission tomography using[(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer[J].J Clin Oncol,2000,18(8):1689-1695.
  • 9Herrada J,Iyer R B,Atkinson E N,et al.Relative value of physical examination,mammography,and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma[J].Clin Cancer Res,1997,3(9):1565-1569.
  • 10陈灿铭.局部晚期乳腺癌的治疗[M]//沈镇宙,邵志敏.乳腺肿瘤学.上海:上海科学技术出版社,2005:269-287.

共引文献17

同被引文献11

  • 1Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol, 2011,727:33-51.
  • 2Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncol Rep, 2007, 18: 503-511.
  • 3Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non- small cell lung cancer. Lung Cancer, 2004, 44:231-239.
  • 4Behzadi A, Ung Y, Lowe V, ct al. The role of positron emission tomography in the manzgement of non-small cell lung cancer. Can J Surg, 2009, 52 : 235-242.
  • 5Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-eell lung cancer. J Clin Oncol, 2007, 25:5116-3123.
  • 6Lee DH, Kim S, Lee H, et al. Early prediction of response to first- line therapy using integrated LSF-FDG PET/CT for patients with advanced metastatic non-snmll cell lung cancer. J Tborac Oncol, 2009, 4: 816-21.
  • 7Mudd SR, Voorbach M J, Reuter DR, et al. FDG-PET as a pharmaeodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669- 1672.
  • 8Takahashi R, Hirata H, Tachibana I, et al. Early [18 F] fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228.
  • 9Nahmias C, Hannal WT, Wahl I,M, et al. Time course of early response to chemotherapy in non-small eell lung cancer patients with ISF-FDG PET/CT. J Nucl Med, 2007, 48:744-751.
  • 10Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST : evolving considerations for PET response criteria in solid tumors. J Nucl Med, 2009, 50: 122S-150S.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部